Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice.
Following 28 days of oral administration, in intact mice, the novel non-steroidal anti-estrogen EM-800 was at least 30-fold more potent than tamoxifen in inhibiting uterine weight. Moreover, the maximal inhibitory effect achieved with tamoxifen on uterine weight was only 40% that with EM-800. The pure anti-estrogenic activity of EM-800 on the hypothalamo-pituitary-gonadal axis is illustrated by the increase in ovarian weight, while tamoxifen, due to its estrogenic activity, decreased ovarian weight. EM-800 is 10- to 30-fold more potent than tamoxifen in inhibiting uterine and vaginal estrogen receptors. Since 17beta-hydroxysteroid dehydrogenase (17beta-HSD) is the key enzyme in estradiol formation, the potent inhibitory effect of EM-800 on uterine 17beta-HSD could play an additional role by decreasing the availability of estradiol in the uterine tissue, while tamoxifen, on the contrary, stimulates activity of the enzyme. The atrophic changes in both the endometrial and myometrial layers achieved with EM-800 almost reached those observed 28 days after ovariectomy. EM-800 also resulted in a marked decrease in the number of ovarian developing follicles and corpora lutea, while the number of atretic follicles was increased. Tamoxifen treatment, on the other hand, produced an increase in both the number and crowding of the endometrial glands and a mild atrophy of the myometrial layer. Tamoxifen caused atrophic changes of the vaginal epithelium, especially at the highest doses, though the atrophy was much less pronounced than that following EM-800 treatment or ovariectomy. In addition to being at least 30-fold more potent than tamoxifen in inhibiting uterine weight, the novel anti-estrogen causes atrophy of the endometrium, stimulates the hypothalamo-pituitary-gonadal axis and inhibits uterine 17beta-HSD activity, while tamoxifen exerts opposite and estrogen-like effects on these parameters.
Luo
S
S
Laboratory of Molecular Endocrinology, CHUL Research Center, Centre Hospitalier Universitaire de Québec, Canada.
Martel
C
C
Sourla
A
A
Gauthier
S
S
Mérand
Y
Y
Belanger
A
A
Labrie
C
C
Labrie
F
F
D015067:17-Hydroxysteroid Dehydrogenases / Q000187:drug effects; D000735:Androstenedione / Q000378:metabolism; D000818:Animals; D001284:Atrophy / Q000139:chemically induced; D001578:Benzopyrans / Q000008:administration & dosage / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004717:Endometrium / Q000033:anatomy & histology / Q000187:drug effects; D004958:Estradiol / Q000378:metabolism; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D004970:Estrone / Q000378:metabolism; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size / Q000187:drug effects; D010052:Ovariectomy; D011422:Propionates / Q000008:administration & dosage / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000187:drug effects; D013629:Tamoxifen / Q000008:administration & dosage / Q000494:pharmacology*; D013739:Testosterone / Q000378:metabolism; D014599:Uterus / Q000033:anatomy & histology / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D014621:Vagina / Q000033:anatomy & histology / Q000187:drug effects*
D001578:Benzopyrans; D004965:Estrogen Antagonists; D011422:Propionates; D011960:Receptors, Estrogen; D013629:Tamoxifen; D004970:Estrone; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D015067:17-Hydroxysteroid Dehydrogenases; C044256:3 (or 17)-beta-hydroxysteroid dehydrogenase; C106945:EM 800